Company / Cost of Revenue
Protalix BioTherapeutics, Inc. Cost of Revenue History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$23.0M
FY2025
5-year range
$10.9M / $23.0M
FY2021-FY2025
Trend
+17.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue has increased for 3 consecutive years, from $11M in FY2022 to $23M in FY2025.
Based on SEC 10-K filings.
$23M in FY2025 with a 5-year CAGR of +19.8%.
Increased from $16M to $23M over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +28.3%
- 5-Year CAGR
- +19.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- Protalix BioTherapeutics, Inc.'s cost of revenue has grown for 3 consecutive years.
- 5-year CAGR of +19.8%, indicating consistent growth.
- In FY2025, cost of revenue increased 17.3% year-over-year.
- Lowest cost of revenue in the period was in FY2015.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $23.0M | +17.3% |
| FY2024 | $19.6M | +19.8% |
| FY2023 | $16.3M | +50.4% |
| FY2022 | $10.9M | -0.2% |
| FY2021 | $10.9M | +17.1% |
| FY2020 | $9.3M | -38.9% |
| FY2019 | $15.2M | +1986.4% |
| FY2017 | $730.0K | +15.9% |
| FY2016 | $630.0K | - |
| FY2015 | $0 | -100.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026